Alcoholic liver diseases are the result of overconsumption of alcohol, which damages the liver, leading to liver cirrhosis, inflammation, and liver scarring. Alcohol remains the most common cause of chronic diseases in the United States and other Western countries. The liver is one of the vital organs of the body, which performs various functions such as regulating cholesterol and blood sugar, filtering out blood toxins, and many others. The symptoms of alcoholic liver diseases generally develop in middle age between 30-40 years. The range of clinical features of alcoholic liver diseases varies widely from asymptomatic to end-stage liver diseases. The major symptoms of alcoholic liver diseases are portal hypertension, jaundice, abdominal pain, diarrhea, and many more. According to CDC (Centers for Disease Control and Prevention), the number of deaths from alcoholic liver diseases was 19,388 in the year 2014. Alcoholic liver diseases are one of the main reasons for liver transplantation. There are four main stages of alcoholic liver diseases - alcoholic fatty liver disease, alcoholic liver hepatitis, liver fibrosis, and liver cirrhosis. According to NHS (National Health Services), alcoholic liver diseases accounted for 82% of overall alcohol-specific deaths. Abstinence and lifestyle modifications, pharmacotherapy, nutritional supplements, and several other medications improve the survival rate in alcoholic cirrhotic patients.
Alcoholic Liver Diseases Treatment Market: Drivers and Restraints
Rapidly changing lifestyle pattern such as increasing alcohol consumption and unhealthy diets are the factors driving the alcoholic liver diseases treatment market. The increasing prevalence of liver diseases is also expected to boost the alcoholic liver diseases treatment market during the stated forecast period. Rising R&D funding by governments for the development of novel therapies to treat chronic liver diseases also escalates the market for alcoholic liver diseases treatment. The side effects associated with medications are expected to hamper the growth of the Alcoholic Liver Diseases Treatment market during the overall forecast period. Stringent government regulations for the approval of drugs also decline the growth of the alcoholic liver diseases treatment market. Lack of awareness and poor diagnosis facilities in the low economic regions also degrade the alcoholic liver diseases treatment market.
Alcoholic Liver Diseases Treatment Market: Segmentation
The global alcoholic liver diseases treatment market can be segmented on the basis of indication, treatment, distribution channel, and geography.
Based on indication, the global alcoholic liver diseases treatment market is segmented as:
- Alcoholic Fatty Liver Disease
- Alcoholic Liver Hepatitis
- Liver Fibrosis
- Liver Cirrhosis
Based on treatment, the global alcoholic liver diseases treatment market is segmented as:
Based on distribution channel, the global alcoholic liver diseases treatment market is segmented as:
- Hospital Pharmacies
- Retail Pharmacies
- Drug Stores
- Online Pharmacies
Alcoholic Liver Diseases Treatment Market: Overview
The global market for alcoholic liver diseases treatment is expected to witness high growth over the forecast period. Alcoholic liver diseases can cause severe complications. Steroids and pharmacotherapies hold the largest market share in the alcoholic liver diseases treatment market. Nutritional supplements such as betaine have shown to reduce disease severity. Alcohol consumption has become quite common, and the increasing prevalence of alcoholic liver diseases is expected to lead to the robust growth of the alcoholic liver diseases treatment market. Early detection reduces the progression of further liver damage. However, a majority of drugs are introduced in the generic form in Alcoholic Liver Diseases Treatment market, and thus, there exists high competition among local and regional players.
Alcoholic Liver Diseases Treatment Market: Regional Outlook
Geographically, the global alcoholic liver diseases treatment market is segmented into North America, Latin America, Europe, Asia Pacific excluding Japan (APEJ), Japan, and the Middle East and Africa (MEA). The North American alcoholic liver diseases treatment market is expected to be the dominant market in the global alcoholic liver diseases treatment market, owing to the high prevalence of the alcoholic liver diseases, and an increase in the consumption of alcohol. The European alcoholic liver diseases treatment market is expected to have the second-largest share in the global alcoholic liver diseases treatment market throughout the forecast period, due to modern lifestyles. The alcoholic liver diseases treatment market in Asia Pacific is also expected to grow at a significant rate, due to lifestyle changes and the lack of awareness among individuals. The Middle East and African region shows moderate growth in the alcoholic liver diseases treatment market, due to poor diagnosis facilities and lack of awareness among patients.
Alcoholic Liver Diseases Treatment Market: Key Players
Examples of some of the key players operating in the global alcoholic liver diseases treatment market are Johnson & Johnson Services, Inc., Sanofi, Upsher-Smith Laboratories, LLC, F. Hoffmann-La Roche AG, Novartis AG, GlaxoSmithKline plc, Pfizer Inc., Bayer AG, and many others.
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, and inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators, and governing factors, along with market attractiveness as per segment. The report also maps the qualitative impact of various market factors on market segments and geographies.
The report covers exhaustive analysis on:
- Market Segments
- Market Dynamics
- Market Size
- Supply & Demand
- Current Trends/Issues/Challenges
- Competition & Companies Involved
- Value Chain
Regional analysis includes:
- North America (U.S., Canada)
- Latin America (Mexico, Brazil, Argentina, Chile, Peru, Rest of LatAm)
- Europe (Germany, Italy, U.K, Spain, France, Nordic Countries, BENELUX, Eastern Europe and Rest of Europe)
- CIS & Russia
- Asia Pacific Excluding Japan (China, India, S. Korea, ASEAN Countries, Rest of APEJ)
- Middle East and Africa (GCC, S. Africa, Turkey, Iran, Israel, Rest of MEA)
- Detailed overview of parent market
- Changing market dynamics in the industry
- In-depth market segmentation
- Historical, current and projected market size in terms of volume and value
- Recent industry trends and developments
- Competitive landscape
- Strategies of key players and products offered
- Potential and niche segments, geographical regions exhibiting promising growth
- A neutral perspective on market performance
- Must-have information for market players to sustain and enhance their market footprint
Benefits of Becoming a Fact.MR Client
- Access to our global market coverage
- Periodic updates on your sector
- Exclusive discounts and offers
- Greater flexibility for customization
- Quick-research assistance for ad-hoc needs
- Access to credible insights Fact.MR analyst interactions
- Access to Fact.MR tools and research to fuel strategy development